Depot formulation of olanzapine as effective and safe as oral formulation

Data from clinical trials investigating the long-acting injectable (LAI) form of the atypical antipsychotic olanzapine were presented at the first annual Schizophrenia International Research Society (SIRS) Conference in Venice, Italy [1]. These data indicate that the efficacy and safety profile of olanzapine LAI is generally consistent with that of oral olanzapine (Zyprexa), with the exception of injection-related events.

It is generally accepted that olanzapine is a valuable tool in the treatment of schizophrenia, and the drug has been prescribed to approximately 24 million people worldwide since it was introduced in 1996. Olanzapine LAI is an investigational formulation that combines the antipsychotic with a pamoate salt, resulting in an extended delivery of up to 4 weeks.

Non-adherence to prescribed antipsychotic medication regimens is a major problem in the long-term treatment of schizophrenia [2]. By administering LAI antipsychotics (also known as depot antipsychotics), healthcare professionals can immediately detect and act upon non-adherence (that is, when a person fails to return for a scheduled injection) [3]. Thus, LAI formulations should be considered as a treatment option when a person expresses a preference for such treatment due to convenience, or if it is determined that a depot formulation is necessary to help avoid non-adherence to oral medications.

"These studies offer insight into the potential of olanzapine LAI as a maintenance treatment for patients with schizophrenia who may have difficulty taking medication on a daily basis," said David McDonnell, M.D., clinical research physician at Lilly. "Schizophrenia is a challenging and complex disease to manage, which is why finding new ways to support patient compliance with medication is so important."

Regulatory reviews of olanzapine LAI applications are ongoing in the European Union, Canada, Australia and United States. 

[1] Schizophrenia International Research Society (SIRS) Conference, 21–25 June, 2008, Venice, Italy 

[2] Falkai P et al. Task Force On Treatment Guidelines For Schizophrenia. The World Journal of Biological Psychiatry 2006;7(1):5–40

[3] Kane JM et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology 1998;8(1):55–66